PURPOSE: In a previous study, restricting intravenous chloride administration in ICU patients decreased the incidence of acute kidney injury (AKI). To test the robustness of this finding, we extended our observation period to 12 months. METHODS: The study extension included a 1-year control period (18 August 2007 to 17 August 2008) and a 1-year intervention period (18 February 2009 to 17 February 2010). During the extended control period, patients received standard intravenous fluids. During the extended intervention period, we continued to restrict all chloride-rich fluids. We used the Kidney Disease: Improving Global Outcomes (KDIGO) staging to define AKI. RESULTS: We studied 1,476 control and 1,518 intervention patients. Stages 2 and 3 of KDIGO defined AKI decreased from 302 (20.5 %; 95 % CI, 18.5-22.6 %) to 238 (15.7 %; 95 % CI, 13.9-17.6 %) (P < 0.001) and the use of RRT from 144 (9.8 %; 95 % CI, 8.3-11.4 %) to 103 (6.8 %; 95 % CI, 5.6-8.2 %) (P = 0.003). After adjustment for relevant covariates, liberal chloride therapy remained associated with a greater risk of KDIGO stages 2 and 3 [hazard ratio 1.32 (95 % CI 1.11-1.58); P = 0.002] and use of RRT [hazard ratio 1.44 (95 % CI 1.10-1.88); P = 0.006]. However, on sensitivity assessment of each 6-month period, KDIGO stages 2 and 3 increased in the new extended intervention period compared with the original intervention period. CONCLUSIONS: On extended assessment, the overall impact of restricting chloride-rich fluids on AKI remained. However, sensitivity analysis suggested that other unidentified confounders may have also contributed to fluctuations in the incidence of AKI.
PURPOSE: In a previous study, restricting intravenous chloride administration in ICU patients decreased the incidence of acute kidney injury (AKI). To test the robustness of this finding, we extended our observation period to 12 months. METHODS: The study extension included a 1-year control period (18 August 2007 to 17 August 2008) and a 1-year intervention period (18 February 2009 to 17 February 2010). During the extended control period, patients received standard intravenous fluids. During the extended intervention period, we continued to restrict all chloride-rich fluids. We used the Kidney Disease: Improving Global Outcomes (KDIGO) staging to define AKI. RESULTS: We studied 1,476 control and 1,518 intervention patients. Stages 2 and 3 of KDIGO defined AKI decreased from 302 (20.5 %; 95 % CI, 18.5-22.6 %) to 238 (15.7 %; 95 % CI, 13.9-17.6 %) (P < 0.001) and the use of RRT from 144 (9.8 %; 95 % CI, 8.3-11.4 %) to 103 (6.8 %; 95 % CI, 5.6-8.2 %) (P = 0.003). After adjustment for relevant covariates, liberal chloride therapy remained associated with a greater risk of KDIGO stages 2 and 3 [hazard ratio 1.32 (95 % CI 1.11-1.58); P = 0.002] and use of RRT [hazard ratio 1.44 (95 % CI 1.10-1.88); P = 0.006]. However, on sensitivity assessment of each 6-month period, KDIGO stages 2 and 3 increased in the new extended intervention period compared with the original intervention period. CONCLUSIONS: On extended assessment, the overall impact of restricting chloride-rich fluids on AKI remained. However, sensitivity analysis suggested that other unidentified confounders may have also contributed to fluctuations in the incidence of AKI.
Authors: Andrew D Shaw; Sean M Bagshaw; Stuart L Goldstein; Lynette A Scherer; Michael Duan; Carol R Schermer; John A Kellum Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Karthik Raghunathan; Andrew Shaw; Brian Nathanson; Til Stürmer; Alan Brookhart; Mihaela S Stefan; Soko Setoguchi; Chris Beadles; Peter K Lindenauer Journal: Crit Care Med Date: 2014-07 Impact factor: 7.598
Authors: Lu Ke; Paolo Calzavacca; Michael Bailey; Clive N May; Wei-Qin Li; Joseph Bertolini; Rinaldo Bellomo Journal: Crit Care Resusc Date: 2014-03 Impact factor: 2.159
Authors: Paul S Chan; Adnan Khalid; Lance S Longmore; Robert A Berg; Mikhail Kosiborod; John A Spertus Journal: JAMA Date: 2008-12-03 Impact factor: 56.272
Authors: Nor'azim Mohd Yunos; Rinaldo Bellomo; Colin Hegarty; David Story; Lisa Ho; Michael Bailey Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: Andrew D Shaw; Karthik Raghunathan; Fred W Peyerl; Sibyl H Munson; Scott M Paluszkiewicz; Carol R Schermer Journal: Intensive Care Med Date: 2014-10-08 Impact factor: 17.440
Authors: Ayan Sen; Christopher M Keener; Florentina E Sileanu; Emily Foldes; Gilles Clermont; Raghavan Murugan; John A Kellum Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598
Authors: Matthew F Barhight; Jennifer Lusk; John Brinton; Timothy Stidham; Danielle E Soranno; Sarah Faubel; Jens Goebel; Peter M Mourani; Katja M Gist Journal: Pediatr Nephrol Date: 2018-02-05 Impact factor: 3.714
Authors: N E Hammond; C Taylor; M Saxena; B Liu; S Finfer; P Glass; I Seppelt; L Willenberg; J Myburgh Journal: Intensive Care Med Date: 2015-06-03 Impact factor: 17.440
Authors: Johan Mårtensson; Shailesh Bihari; Jonathan Bannard-Smith; Neil J Glassford; Patryck Lloyd-Donald; Luca Cioccari; Nora Luethi; Aiko Tanaka; Marco Crisman; Nicolas Rey de Castro; Marcus Ottochian; Agnes Huang; Maria Cronhjort; Andrew D Bersten; Shivesh Prakash; Michael Bailey; Glenn M Eastwood; Rinaldo Bellomo Journal: Intensive Care Med Date: 2018-10-21 Impact factor: 17.440
Authors: Sadudee Peerapornratana; Carlos L Manrique-Caballero; Hernando Gómez; John A Kellum Journal: Kidney Int Date: 2019-06-07 Impact factor: 10.612
Authors: Anders Perner; Anthony C Gordon; Daniel De Backer; George Dimopoulos; James A Russell; Jeffrey Lipman; Jens-Ulrik Jensen; John Myburgh; Mervyn Singer; Rinaldo Bellomo; Timothy Walsh Journal: Intensive Care Med Date: 2016-10-01 Impact factor: 17.440
Authors: Andrew Friederich; Natalie Martin; Morgan B Swanson; Brett A Faine; Nicholas M Mohr Journal: Ann Emerg Med Date: 2018-08-23 Impact factor: 5.721